{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:27:11Z","timestamp":1787318831482,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, is approved in the USA, the European Union, Japan, South Korea, China and other countries for the treatment of moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of deucravacitinib in Asian patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the 52-week blinded phase III POETYK PSO-3 trial (NCT04167462), patients were randomized 1 : 2 to placebo (n = 74) or deucravacitinib 6\u2005mg once daily (n = 146) for 16 weeks followed by deucravacitinib alone. Co-primary endpoints were the achievement of a \u226575% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment score of 0 (clear) or 1 (almost clear; sPGA 0\/1) at week 16. Efficacy and safety were evaluated throughout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week 16, significantly higher proportions of patients receiving deucravacitinib compared with placebo achieved PASI 75 (68.8% vs. 8.1%; P &amp;lt; 0.001) and sPGA 0\/1 (55.6% vs. 6.8%; P &amp;lt; 0.001). Response rates with deucravacitinib were maintained through week 52. Common adverse events (AEs) included upper respiratory tract infection and nasopharyngitis. Serious AE and discontinuation rates were low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Deucravacitinib was efficacious and well tolerated in Asian patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljae406","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T08:15:59Z","timestamp":1729412159000},"page":"402-409","source":"Crossref","is-referenced-by-count":20,"title":["Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a\u00a0phase III randomized clinical trial"],"prefix":"10.1093","volume":"192","author":[{"given":"Jianzhong","family":"Zhang","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfeng","family":"Ding","sequence":"additional","affiliation":[{"name":"Shanghai Skin Disease Hospital , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Friendship Hospital , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Pan","sequence":"additional","affiliation":[{"name":"People\u2019s Hospital of Zhejiang Province , Hangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7159-879X","authenticated-orcid":false,"given":"Yan","family":"Lu","sequence":"additional","affiliation":[{"name":"Jiangsu Province Hospital , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Sir Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jiang","sequence":"additional","affiliation":[{"name":"West China Hospital of Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Chen","family":"Ho","sequence":"additional","affiliation":[{"name":"Kaohsiung Chang Gung Memorial Hospital , Kaohsiung ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Guo","sequence":"additional","affiliation":[{"name":"First Hospital of Shanxi Medical University , Taiyuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Liu","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkendu","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata M","family":"Kisa","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"2025021810040624300_ljae406-B1","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025021810040624300_ljae406-B2","article-title":"Package insert","author":"Sotyktu"},{"key":"2025021810040624300_ljae406-B3","volume-title":"Package insert","author":"Sotyktu","year":"2022"},{"key":"2025021810040624300_ljae406-B4","article-title":"Product information","author":"Sotyktu"},{"key":"2025021810040624300_ljae406-B5","article-title":"Product monograph (Canada)","author":"Sotyktu"},{"key":"2025021810040624300_ljae406-B6","article-title":"European summary of product characteristics","author":"Sotyktu"},{"key":"2025021810040624300_ljae406-B7","volume-title":"Package insert","author":"Sotyktu","year":"2023"},{"key":"2025021810040624300_ljae406-B8","volume-title":"Package insert","author":"Sotyktu","year":"2023"},{"key":"2025021810040624300_ljae406-B9","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"key":"2025021810040624300_ljae406-B10","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"2025021810040624300_ljae406-B11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025021810040624300_ljae406-B12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, \u00addouble-blinded, Program fOr Evaluation of TYK2 inhibitor psoriasis second phase 3 trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025021810040624300_ljae406-B13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40257-017-0332-7","article-title":"Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial\/ethnic groups","volume":"19","author":"Kaufman","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2025021810040624300_ljae406-B14","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"2025021810040624300_ljae406-B15","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/1346-8138.16740","article-title":"Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial","volume":"50","author":"Imafuku","year":"2023","journal-title":"J Dermatol"},{"key":"2025021810040624300_ljae406-B16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/1346-8138.17074","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, phase 3 trial","volume":"51","author":"Imafuku","year":"2024","journal-title":"J Dermatol"},{"key":"2025021810040624300_ljae406-B17","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0"},{"key":"2025021810040624300_ljae406-B18","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/CM9.0000000000001163","article-title":"Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"2025021810040624300_ljae406-B19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/JD9.0000000000000244","article-title":"Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study","volume":"5","author":"Li","year":"2022","journal-title":"Int J Dermatol Venereol"},{"key":"2025021810040624300_ljae406-B20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci"},{"key":"2025021810040624300_ljae406-B21","first-page":"166","article-title":"Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)","volume":"12","author":"Zhu","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"2025021810040624300_ljae406-B22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-\u00adblind study","volume":"31","author":"Cai","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025021810040624300_ljae406-B23","first-page":"1845","article-title":"Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial","volume":"125","author":"Yang","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"2025021810040624300_ljae406-B24","first-page":"33","article-title":"Management of scalp psoriasis: current perspectives","volume":"6","author":"Blakely","year":"2016","journal-title":"Psoriasis (Auckland, NZ)"},{"key":"2025021810040624300_ljae406-B25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ced.14314","article-title":"Management of nail psoriasis","volume":"46","author":"Thomas","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2025021810040624300_ljae406-B26","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025021810040624300_ljae406-B27","doi-asserted-by":"crossref","article-title":"Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO study program","author":"Lebwohl","DOI":"10.25251\/skin.7.supp.118"},{"key":"2025021810040624300_ljae406-B28","article-title":"Deucravacitinib in plaque psoriasis: 3\u2005year safety and efficacy results from the phase 3 POETYK PSO 1 and PSO 2 trials","author":"Armstrong"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae406\/59972644\/ljae406.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae406\/59972644\/ljae406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae406\/59972644\/ljae406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T05:04:22Z","timestamp":1739855062000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/3\/402\/7831541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,22]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae406","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,10,22]]}}}